Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Texas Right to Know Calls on US to Consider COVID-19 Ozone Therapy After It Shows Promise in Italy


News provided by

Texas Right to Know

Apr 02, 2020, 11:11 ET

Share this article

Share toX

Share this article

Share toX

BRADY, Texas, April 2, 2020 /PRNewswire/ -- With a coalition of state, national and international physicians and researchers, Sheila Hemphill, CEO of Texas Right to Know, is calling to action US state and federal agencies to consider the use of medical ozone as a safe adjuvant therapy option for the treatment of COVID-19. 

"While physicians in other countries are using medical ozone for treatment of COVID-19, few physicians in the United States are using this safe, inexpensive, adjuvant therapy," states Hemphill.  On April 1, Hemphill conducted an on-line meeting featuring Italian physician, Marianno Franzini, President of the Scientific Society of Oxygen-Ozone Therapy (SIOOT) International, Robert Rowen, MD, RowenSu Clinic, Santa Rosa, California, several US physicians and researchers, and a university participant from Greece.

Professor Marianno Franzini stated, "On 24 March 2020, I received a letter from the ISS - Istituto Superiore di Sanità (Higher Institute of Health), stating, 'since the proposal seems to be shared and supported by clinical centers experienced in the treatment of viral pneumonia, it was considered appropriate that the treatment could be carried out under the responsibility of the physician after obtaining the patient's consent.'"  He continued, "Medical ozone helps improve oxygenation and proved effective for SARS in 2002.  Currently there are 17 hospitals using SIOOT oxygen ozone therapy to treat people affected by COVID-19.  From preliminary reports from autopsies of those who died from COVID-19, it appears that the virus immediately attacks the microcirculation system causing widespread thrombosis.  Several hospitals are using Major AutoHemo Therapy (MAHT), a protocol that extracts the patient's blood, bubbles oxygen ozone through the blood in a saline or heparin bag, and is infused back into the patient.  Patients showed clinical improvement in 1-2 days of receiving one infusion, one time a day. The earlier you treat the person the better the results you have."

On the April 1, 2020, the SIOOT reports, "After practicing Oxygen Ozone Therapy, the doctors found the following evidence: a general improvement in clinical conditions, normalization of body temperature, a reduction in C Reactive Protein (PRC), normalization of heart rate, an improvement in saturation and reduction in oxygen support, normalization of renal function (creatinine)."

Professor Luigi Valdenassi, toxicologist, University of Pavia, explains, "I want to specify almost all these patients experience improvement in hypoxemia in a short period that stabilizes their breathing and the creatinine becomes normalized, which is important for function of the kidneys.  Oxygen Ozone therapy could contribute to the prevention of intubation and acute renal failure, both complications of COVID-19, resulting in the need for ventilator support via a breathing tube and dialysis requiring Intensive care unit support."

According to Tommy Swate, SM.hg, MD. JD, a graduate from Tulane School of Public Health and Tropical Medicine, "Based on the Italian reports, it is reasonable to believe that medical ozone may be an effective adjuvant to use in treating COVID-19. Medical ozone's known and potential benefits when used as an adjuvant to standard COVID-19 treatment out weights the very small, if any potential risk of its use." 

"Ozone has been used to treat other viral infections with minimal complications and is being reported to be effective for COVID-19 treatment," said Dr. Robert Rowen.  On March 6, Dr. Rowen's article, "A Plausible 'Penny' Costing Effective Treatment for Corona Virus – Ozone Therapy", was published in the Journal of Infectious Disease and Epidemiology. 

Peter Jovanovic, Executive Director, Ozone Without Borders Society for the Advancement of Bio-Oxidative Therapy British Columbia Member Society reports, "We now know of one Sierra Leone physician, COVID positive whose symptoms abated about 4 hours after ozone treatment and one American COVID positive patient who was essentially normal one day after a single direct intravenous gas treatment. A Spanish physician with high exposure risk and all the symptoms of COVID cleared his symptoms within a day or two of treatment."

Dr. Lamberto Re, MD Chairman of the Scientific Committee Board of World Federation of Oxygen-Oxygen Therapy since 2015 emailed to Hemphill, "Following the approval of some Italian hospitals (https://www.wfoot.org/wp-content/uploads/2020/03/App-5966.pdf.pdf), use of medical ozone certainly should be considered as an adjuvant therapy for the treatment of COVID-19."

About:
Texas Right To Know (TRTK) is a coalition of various advocacy groups with services designed to inform and connect people in a community regarding local and state legislative issues.

Publication and videos by Dr. Marianno Franzini, Dr. Robert Rowen, and other physicians regarding safety and efficacy of ozone treatment are located at www.texasrighttoknow.com.

Media Contact:  Sheila Hemphill, [email protected]

SOURCE Texas Right to Know

Related Links

http://www.texasrighttoknow.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Texas Right to Know: Pending Texas Legislation Only Teaches Jewish Holocaust While Excluding the Many Others

Headed to the Texas House Calendar's Committee, is SB735 by Senator Jose Menendez, "Relating to Holocaust education and training provided to students ...

Texas Right to Know:"Claims of Jews Killing Jesus" Punishable as Antisemitism Under Current Texas Law

Members of the Texas Senate Education K-16 Committee, chaired by Brandon Creighton (Conroe), and the House State Affairs Committee, chaired by Ken...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Infection Control

Infection Control

Medical Pharmaceuticals

Medical Pharmaceuticals

Advocacy Group Opinion

Advocacy Group Opinion

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.